RS-8359 | TUK-9262 | TUK9262 | CAS#105365-76-2 | MAO-A inhibitor

MedKoo Cat#: 526897 | Name: RS-8359

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RS-8359, also known as TUK-9261; TUK-9262, is a selective and reversible MAO-A inhibitor potentially for treatment of depression.

Chemical Structure

RS-8359

CAS#105365-76-2

Theoretical Analysis

MedKoo Cat#: 526897

Name: RS-8359

CAS#: 105365-76-2

Chemical Formula: C14H12N4O

Exact Mass: 252.1011

Molecular Weight: 252.28

Elemental Analysis: C, 66.65; H, 4.79; N, 22.21; O, 6.34

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

RS-8359; RS 8359; RS8359; TUK-9261; TUK-9262; TUK9261; TUK9262.

IUPAC/Chemical Name

4-(4-Cyanoanilino)-6,7-dihydro-7-hydroxy-5H-cyclopenta(d)pyrimidine

InChi Key

YKTSVZRWKHWINV-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H12N4O/c15-7-9-1-3-10(4-2-9)18-14-11-5-6-12(19)13(11)16-8-17-14/h1-4,8,12,19H,5-6H2,(H,16,17,18)

SMILES Code

OC1CCC2=C(NC3=CC=C(C#N)C=C3)N=CN=C21

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 252.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Itoh K, Hoshino K, Endo A, Asakawa T, Yamakami K, Noji C, Kosaka T, Tanaka Y. Chiral inversion of RS-8359: a selective and reversible MAO-A inhibitor via oxido-reduction of keto-alcohol. Chirality. 2006 Sep;18(9):698-706. PubMed PMID: 16823812. 2: Itoh K, Nishiya Y, Takasaki W, Adachi M, Tanaka Y. Enantioselective 2-hydroxylation of RS-8359, a selective and reversible MAO-A inhibitor, by cytochrome P450 in mouse and rat liver microsomes. Chirality. 2006 Aug;18(8):592-8. PubMed PMID: 16642492. 3: Sasaki T, Masubuchi A, Yamamura M, Watanabe N, Hiratsuka M, Mizugaki M, Itoh K, Tanaka Y. Rat strain differences in stereospecific 2-oxidation of RS-8359, a reversible and selective MAO-A inhibitor, by aldehyde oxidase. Biopharm Drug Dispos. 2006 Jul;27(5):247-55. PubMed PMID: 16586463. 4: Itoh K, Yamamura M, Takasaki W, Sasaki T, Masubuchi A, Tanaka Y. Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharm Drug Dispos. 2006 Apr;27(3):133-9. PubMed PMID: 16400710. 5: Itoh K, Yamamura M, Muramatsu S, Hoshino K, Masubuchi A, Sasaki T, Tanaka Y. Stereospecific oxidation of the (S)-enantiomer of RS-8359, a selective and reversible monoamine oxidase A (MAO-A) inhibitor, by aldehyde oxidase. Xenobiotica. 2005 Jun;35(6):561-73. PubMed PMID: 16192108. 6: Takasaki W, Yamamura M, Nozaki A, Nitanai T, Sasahara K, Itoh K, Tanaka Y. Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug-metabolizing enzymes. Chirality. 2005 Mar;17(3):135-41. PubMed PMID: 15704197. 7: RS 8359. Drugs R D. 1999 Jul;2(1):63-5. PubMed PMID: 10610287. 8: Takasaki W, Yamamura M, Shigehara E, Suzuki Y, Tonohiro T, Hara T, Tanaka Y. Stereoselective pharmacokinetics of RS-8359, a selective and reversible inhibitor of A-type monoamine oxidase, in rats, mice, dogs, and monkeys. Biol Pharm Bull. 1999 May;22(5):498-503. PubMed PMID: 10375171. 9: Püchler K, Plenker A, Volz HP. Safety, tolerability and efficacy of the reversible monoamine oxidase inhibitor RS-8359 in early clinical trials. Int Clin Psychopharmacol. 1997 Sep;12 Suppl 5:S31-6. PubMed PMID: 9466167. 10: Plenker A, Püchler K, Volz HP. The effects of RS-8359 on cardiovascular function in healthy subjects and depressed patients. Int Clin Psychopharmacol. 1997 Sep;12 Suppl 5:S25-9. PubMed PMID: 9466166. 11: Püchler K, Schaffler K, Plenker A. The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects. Int Clin Psychopharmacol. 1997 Sep;12 Suppl 5:S17-23. PubMed PMID: 9466165. 12: Püchler K, Sasahara K, Plenker A, Nitanai T, Witte PU. The pharmacokinetic profile of RS-8359. Int Clin Psychopharmacol. 1997 Sep;12 Suppl 5:S11-6. PubMed PMID: 9466164. 13: Iwata N, Püchler K, Plenker A. Pharmacology of the new reversible inhibitor of monoamine oxidase A, RS-8359. Int Clin Psychopharmacol. 1997 Sep;12 Suppl 5:S3-10. PubMed PMID: 9466163. 14: Kozuka M, Kobayashi K, Iwata N. Effects of RS-8359 on reduced local cerebral glucose utilization in the rat subjected to transient forebrain ischemia. Jpn J Pharmacol. 1994 Apr;64(4):257-64. PubMed PMID: 8057526. 15: Miura H, Naoi M, Nakahara D, Ohta T, Nagatsu T. Changes in monoamine levels in mouse brain elicited by forced-swimming stress, and the protective effect of a new monoamine oxidase inhibitor, RS-8359. J Neural Transm Gen Sect. 1993;94(3):175-87. PubMed PMID: 8123229. 16: Kumagae Y, Matsui Y, Iwata N. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J Pharmacol. 1991 Jan;55(1):121-8. PubMed PMID: 1904113. 17: Yokoyama T, Karube T, Iwata N. Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in-vitro and in-vivo in mouse brain. J Pharm Pharmacol. 1989 Jan;41(1):32-6. PubMed PMID: 2565961.